Stoke Therapeutics STOK
Stoke Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$26.41+1.07%close on Oct. 28, 2026 · volume 781K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 2, 2026 | Jonathan Allan GENERAL COUNSEL & CORP SEC | Sold 10b5-1 plan | 627 | $26.33 | $16,509 |
| Oct. 1, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | Sold 10b5-1 plan | 1,051 | $26.16 | $27,494 |
| Sept. 1, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | Sold 10b5-1 plan | 5,545 | $30.67 $30.51-$31.06 | $170,061 |
| Aug. 18, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | Sold | 4,767 | $32.03 $32.01-$32.47 | $152,690 |
| Aug. 18, 2026 | Edward M. Md Kaye director | Sold | 12,567 | $32.03 $32.01-$32.47 | $402,528 |
| Aug. 18, 2026 | Jonathan Allan GENERAL COUNSEL & CORP SEC | Sold | 2,861 | $32.03 $32.01-$32.47 | $91,639 |
| Aug. 3, 2026 | Barry Ticho CHIEF MEDICAL OFFICER | Sold 10b5-1 plan | 7,176 | $29.04 $28.95-$29.45 | $208,385 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 17 →Departure/appointment of directors or officers